Control Prev
Control Prev

Developing Late Stage Photodynamic Therapy Platform for the Treatment of Serious Oncology Indications

Late-Stage Development Product for Cutaneous Metastatic Breast Cancer (CMBC)

How REM-001 Therapy Works CEO Webcast

Pipeline

Our REM-001 Therapy provided high response rates in treating CMBC tumors in multiple Phase 2 and 3 clinical trials

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
REM-001 Cutaneous Metastatic Breast Cancer
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
Market Phase not started
REM-0011 Other Cutaneous Metastatic Cancers (Lung, Colon, Ovarian)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
REM-001 Bile Duct Cancer
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
Market Phase not started
  1. Approval in CMBC may allow Company to undertake post-marketing label expansion studies in other cutaneous metastatic cancers

Inducing Tumor Cell Death

Photodynamic therapy (PDT) uses photosensitizers that, when exposed to light, act as a catalyst to produce a form of oxygen that induces local tumor cell death.

Our PDT Technology

Developing Novel Therapies to Treat Cancer

We are focused on the development of our photodynamic therapy for the treatment of unmet medical needs, specifically indications in cancer.

About Adgero

Experienced Management Team

Our strong management team and scientific advisory board boast extensive backgrounds in oncology and photodynamic therapy.

Meet Our Team

Corporate Presentation

View our latest corporate presentation

View investor presentation